Sunil Jeetah, a 57-year-old resident of Mauritius, experienced a dramatic health transformation thanks to CAR-T therapy in India. Initially diagnosed with diffuse large B-cell lymphoma (DLBCL), an aggressive form of cancer, Jeetah went through a standard treatment of R-CHOP chemotherapy, achieving remission. However, just four months later, he faced a relapse, prompting further investigation into his treatment options.
Seeking Alternative Treatment Options
Upon learning that no additional treatment was available in Mauritius, Jeetah researched international facilities. He discovered a promising cancer treatment in Mumbai, India, noting the hospital’s responsiveness and the thoroughness of his doctor, Dr. Kunal Goyal. Jeetah stated, “When a doctor is transparent with the outcomes and data, the patient finds the strength to fight from within.” His case was complex, with the cancer having aggressive features and spread beyond the lymph nodes, which usually indicates a poor prognosis.
Understanding CAR-T Therapy
- CAR-T therapy is a cutting-edge treatment designed for aggressive cancers like DLBCL.
- Dr. Goyal emphasized the importance of personalized treatment plans that account for the patient’s overall health and disease characteristics.
The Journey of Treatment
Jeetah began his CAR-T therapy, developed by ImmunoACT in India, which is recognized for its innovative approach and affordability. After a painless infusion, he underwent extensive monitoring during his recovery period. Following his initial treatment, he faced some immune-related complications. However, Dr. Goyal was available for support through phone and messaging, which greatly eased Jeetah’s concerns.
Success After Treatment
Today, Jeetah celebrates over 18 months without evidence of disease. His energy levels have improved significantly, allowing him to return to exercise and regular activities. He remarked, “The side effects of CAR-T were much fewer and less intense than chemotherapy.” His oncologist confirmed that outcomes for early-relapsed lymphoma without CAR-T therapy are typically poor, but CAR-T can provide sustainable disease control for select patients.
A Revolutionary, Affordable Option
Traditionally, CAR-T therapy has been out of reach for many due to its high costs, often exceeding $300,000 in the United States and Europe. However, India has introduced innovation in this field, allowing the production of CAR-T therapy at a significantly lower cost while maintaining high clinical efficacy. Since receiving approval from the Central Drugs Standard Control Organization (CDSCO), ImmunoACT has successfully treated over 650 patients.
Conclusion
For patients like Sunil Jeetah, the availability of CAR-T therapy in India provides a valuable opportunity for treatment where none existed before. The advancements in this therapy not only represent a medical breakthrough but also offer patients hope and improved quality of life.
Note: CAR-T therapy can have severe side effects requiring specialized care. Patients should discuss potential risks and benefits with their healthcare providers before proceeding with treatment.
